Multiplex Assay Kit for Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay)

MGLAP; GIG36; Cell growth-inhibiting gene 36 protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 81-90 85
EDTA plasma(n=5) 78-104 101
heparin plasma(n=5) 82-89 86
sodium citrate plasma(n=5) 94-102 98

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-90% 93-105% 95-102% 93-101%
EDTA plasma(n=5) 95-103% 79-88% 80-95% 85-99%
heparin plasma(n=5) 78-97% 97-105% 95-104% 90-97%
sodium citrate plasma(n=5) 93-102% 98-105% 83-104% 98-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:MGP) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Nephrology Dialysis Transplantation Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells PubMed: PMC3611891
Maturitas. Bone metabolism regulators and arterial stiffness in postmenopausal women Pubmed: 23916080
The Egyptian Rheumatologist Osteoprotegerin (OPG) and Matrix Gla protein (MGP) in rheumatoid arthritis patients: Relation to disease activity ScienceDirect: S1110116414000076
Toxicology Reports Canola and hydrogenated soybean oils accelerate ectopic bone formation induced by implantation of bone morphogenetic protein in mice Researchgate:Source
Lipids in Health and Disease Markers of increased cardiovascular risk in patients with chronic kidney disease Biomedcentral:Source
Human &amp; Veterinary Medicine The behavior of circulating matrix Gla protein, matrix metalloproteinase-9 and nitrotyrosine in patients with varicose veins Hvm:Source
Pol Arch Med Wewn Effect of Vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5 PubMed: 26176325
Lipids Health Dis. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study pmc:PMC4739105
Kidney Blood Press Res. Plasma Desphospho-Uncarboxylated Matrix Gla Protein as a Marker of Kidney Damage and Cardiovascular Risk in Advanced Stage of Chronic Kidney Disease Pubmed:27100101
Archives of Oral Biology Matrix-Gla Protein rs4236 [A/G] gene polymorphism and serum and GCF levels of MGP in patients with subgingival dental calculus pubmed:27348051
Cell Death & Disease Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis Pubmed:29880866
Urology High concentration of calcium promotes mineralization in NRK52E cells via inhibiting the expression of matrix Gla protein Pubmed:29935264
Clinica Chimica Acta Serum total matrix Gla protein: Reference interval in healthy adults and variations in patients with vascular and osteoarticular diseases Pubmed: 30597137
Biological Trace Element Research Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients Pubmed: 30847765
Renal Failure Relationship of matrix Gla protein and vitamin K with vascular calcification in hemodialysis patients Pubmed: 31538831
Heliyon Matrix Gla protein maintains normal and malignant hematopoietic progenitor cells by interacting with bone morphogenetic protein-4 Pubmed: 32322728
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPB477Mu02 Recombinant Matrix Gla Protein (MGP) Positive Control; Immunogen; SDS-PAGE; WB.
RPB477Mu01 Recombinant Matrix Gla Protein (MGP) Positive Control; Immunogen; SDS-PAGE; WB.
PAB477Mu01 Polyclonal Antibody to Matrix Gla Protein (MGP) WB; IHC; ICC; IP.
PAB477Mu02 Polyclonal Antibody to Matrix Gla Protein (MGP) WB; IHC; ICC; IP.
LAB477Mu71 Biotin-Linked Polyclonal Antibody to Matrix Gla Protein (MGP) WB; IHC; ICC.
SEB477Mu ELISA Kit for Matrix Gla Protein (MGP) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB477Mu Multiplex Assay Kit for Matrix Gla Protein (MGP) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.